BRIDGE-BRNCT07518121
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
StatusWithdrawn
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Withdrawn before enrolling Sponsor's reason: PK bridging has been exempted Show 5 more changesShow less
- Primary endpoint(s) modified
- Enrollment target: estimated 48 to confirmed 0
- Eligibility criteria expanded, about 12 words
- Secondary endpoints revised (10)
- Site contact updated
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
Endpoints
Primary
Concentration (Cmax) of YN-011 maximum Observed Plasma
Timeframe: Predose through Day 29
Concentration (Tmax) of YN-011 Time to Maximum Observed Plasma
Timeframe: Predose through Day 29
Concentration (AUC0-t) of YN-011 Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable
Timeframe: Predose through Day 29
Concentration of Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011
Timeframe: Predose through Day 29
Terminal Elimination Half-Life (t1/2) of YN-011
Timeframe: Predose through Day 29
Secondary (10)
Rate of Incidence and severity of adverse events
Rate of Clinically significant changes in vital signs, clinical laboratory tests, and 12-lead electrocardiograms
Change rate of from baseline in fasting plasma glucose
Change Rate of From Baseline in Body Weight
Incidence rate of anti-drug antibodies and neutralizing antibodies
Show 5 moreShow less
Correlation Between AUC0-inf of YN-011 and Change From Baseline in Fasting Plasma Glucose at Day 29
Correlation between AUC0-inf of YN-011 and change from baseline in body weight at Day 29
Comparison of AUC0-inf of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
Comparison of AUC0-t of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
Comparison of Cmax of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
Arms and interventions
YN-011 1mgExperimental
YN-011 3mgExperimental
PlaceboPlacebo comparator
Drugs: Efsubaglutide Alfa Injection, Placebo
Sites
1 site in 1 country
- A2Z Clinical Centro Avançado de Pesquisa Clínica LTDAValinhos, São Paulo, Brazil